NASDAQ:AERI Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.25▼$15.2550-Day Range$15.18▼$15.2552-Week Range$4.81▼$15.37Volume600 shsAverage Volume974,748 shsMarket Capitalization$753.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aerie Pharmaceuticals alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Aerie Pharmaceuticals Stock (NASDAQ:AERI)Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << AERI Stock News HeadlinesMay 10, 2024 | finance.yahoo.comGlobal $20B+ Macular Degeneration Treatment Market Outlook, 2024-2029: AI Integration Paves the Way for Personalized CareFebruary 29, 2024 | uk.finance.yahoo.com20 Countries With Worst Vision ProblemsSeptember 9, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…February 21, 2024 | finance.yahoo.comParatus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive OfficerJanuary 12, 2024 | msn.comJustin Timberlake is ready to Rock Your Body for one night only in Memphis, and for freeJanuary 10, 2024 | msn.comAlcon’s dry eye drug achieves primary endpoints in Phase III trialsJanuary 8, 2024 | finanznachrichten.deCurative Biotechnology, Inc.: Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsJanuary 8, 2024 | markets.businessinsider.comCurative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of DirectorsSeptember 9, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…December 15, 2023 | finance.yahoo.comGlaucoma Therapeutics Market Size Projected to Reach USD 13.5 billion by 2031, With 5.5% CAGR: Transparency Market Research, Inc.November 28, 2023 | finance.yahoo.comGlobal Over the Counter (OTC) Drugs Market Size to Grow USD 265 Billion by 2032 | CAGR of 5.0%November 25, 2023 | nypost.comAerie’s Black Friday Sale is here —Save 40% off sitewide for a limited timeNovember 23, 2023 | finance.yahoo.comNetarsudil for Fuchs Endothelial Corneal Dystrophy (FECD), 2019-2023 Emerging Drug Insights and Forecasts to 2032November 23, 2023 | finance.yahoo.comGlobal Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%October 27, 2023 | finanznachrichten.deOpthea Limited: Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFOOctober 27, 2023 | markets.businessinsider.comOpthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFOOctober 23, 2023 | finance.yahoo.comRetinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsightSeptember 25, 2023 | uk.finance.yahoo.comRising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment MarketSee More Headlines Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today9/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AERI CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,810,000.00 Net Margins-17.09% Pretax Margin-16.47% Return on EquityN/A Return on Assets-2.00% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio1.92 Sales & Book Value Annual Sales$194.13 million Price / Sales3.88 Cash FlowN/A Price / Cash FlowN/A Book Value($3.32) per share Price / Book-4.59Miscellaneous Outstanding Shares49,417,000Free Float47,223,000Market Cap$753.61 million OptionableOptionable Beta-0.06 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Raj Kannan (Age 58)CEO, Principal Financial Officer & Director Comp: $753.49kDr. Casey C. Kopczynski Ph.D. (Age 61)Co-Founder, Chief Innovation Officer & Head of Research and External Innovation Comp: $685.06kMr. John W. LaRocca Esq. (Age 57)Gen. Counsel & Sec. Comp: $676.62kMr. Peter F. Lang (Age 50)Chief Financial Officer Dr. Michelle Senchyna Ph.D.Head of Clinical Devel. & OperationsMr. Jeffrey M. Calabrese CPA (Age 55)VP of Fin. & Principal Accounting Officer Ms. Carolyn McAuliffeSr. Director of CommunicationsMs. Wanda FranciesHead of HRMr. Marvin J. Garrett (Age 71)Head of Regulatory Affairs & Quality Assurance Mr. Craig R. SkenesHead of Bus. Devel.More ExecutivesKey CompetitorsSutro BiopharmaNASDAQ:STROOyster Point PharmaNASDAQ:OYSTMeiraGTxNASDAQ:MGTXAgenusNASDAQ:AGENPrecision BioSciencesNASDAQ:DTILView All Competitors AERI Stock Analysis - Frequently Asked Questions How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The company earned $29.31 million during the quarter, compared to analyst estimates of $29.13 million. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD) and Puma Biotechnology (PBYI). This page (NASDAQ:AERI) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerie Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
